AU2001241802A1 - Urogenital or anorectal transmucosal vaccine delivery system - Google Patents
Urogenital or anorectal transmucosal vaccine delivery systemInfo
- Publication number
- AU2001241802A1 AU2001241802A1 AU2001241802A AU4180201A AU2001241802A1 AU 2001241802 A1 AU2001241802 A1 AU 2001241802A1 AU 2001241802 A AU2001241802 A AU 2001241802A AU 4180201 A AU4180201 A AU 4180201A AU 2001241802 A1 AU2001241802 A1 AU 2001241802A1
- Authority
- AU
- Australia
- Prior art keywords
- suppository
- vaccine
- polyethylene glycol
- delivery system
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE
DELIVERY SYSTEM
Field of Invention The present invention relates generally to a system and method for treating disease
in humans and animals, specifically a prophylactic treatment of viral or microbial infections
in humans or animals. More particularly, the invention relates to a suppository-based,
vaccine delivery system for prophylaxis against or therapy for viral or microbial infections
in humans or animals, wherein the suppository is intended for transmucosal immunization
and is comprised of a vaccine or vaccine adjuvant(s) that is derived from whole or fractionated viral or other microbial pathogens, or their purified cellular constituents or
derivatives, whether native, synthetic, cloned or recombinantly expressed, that consists of
nucleotide sequences, proteins or other antigenic determinants capable of producing humoral
or cellular-mediated immunity in humans or animals. Still more particularly, the present invention relates to a suppository-based, vaccine delivery system for prophylaxis against or
therapy for viral or microbial infections in humans or animals, wherein the suppository is
used for transmucosal immunization and is comprised of a vaccine or vaccine adjuvant(s) intended for mucosal immunization that is derived from whole or fractionated viral or other
microbial pathogens, or their purified cellular constituents, whether native, synthetic, cloned
or recombinantly expressed, that consists of nucleotide sequences, proteins or other antigenic
determinants capable of producing humoral or cellular-mediated immunity in humans or animals, and wherein the suppository is comprised of a suitable base that liquefies or becomes water miscible at body temperature in order to deliver vaccine components and/or
vaccine adjuvant components to the urogenital or anorectal mucosa so as to cause or enhance
the development of a desired immune response.
Background of the Invention Viral and microbial pathogens transmitted through or originating from exposure of
the urogenital or anorectal epithelium or mucosa are a major problem in medicine.
Urogenital and anorectal structures and systemic tissues beyond may be affected. Such infectious disease can result from mucosal exposure during sexual contact or other contact
or from opportunistic growth of the urogenital or anorectal flora.
A tendency for recurrence, reinfection and chronic progression is characteristic of
many urogenital or anorectal tract infections. Viral or microbial adherence to the mucosal
epithelium is frequently a key precondition for the colonization or infection of these tissues. In-vitro studies have shown that the adherence phenomenon is often accomplished via the
pili of bacteria or other outer membrane constituents of infecting viruses or microbes. Such
adherence can be prevented by the development of antibodies and/or enhancement of cell-
mediated immunity against antigenic components of the invading organisms, which include viruses, bacteria, protozoa, fungi and the like.
Bacteria and viruses are the most frequent causative agents of genitourinary or
anorectal tract infections. The genitourinary/anorectal tracts can also be infected by other
microorganisms, such as protozoa, fungi and the like. Recurrence and chronicity are
characteristic of many genintourinary/anorectal tract infections. Recurrence may be due to
either relapse or reinfection.
In spite of a great deal of progress in the treatment of infectious disease, the morbidity
and mortality of genitourinary/anorectal tract infections remains unchanged. The reasons for
this are myriad and depend on the host susceptibility, heightened sexual exposure and on
viral or microbial factors.
Recurrences of infections with a previously infecting organism may result from
inadequacy of the treatment administered because of incorrect choice of medicine, emergence
of resistance strains, insufficient treatment duration, insufficient concentration of
chemo therapeutic agents, the existence of bacterial L- forms, and persistence or survival of viral or microbes in urinary calculi or epithelium of the vaginal or anorectal mucosa and surrounding tissues. Recurrent urogenital/anorectal infections can be reinfections with
different strains of organisms responsible for prior infections and generally having a greater
capacity to adhere to the epithelial cells of the vagina, urethra or rectum. The reinfecting
bacteria can originate in the intestinal flora. Frequently, viruses and chlamydia pathogens may lay dormant in epithelial cells and revert to an active state through mechanisms not fully
understood.
The composition of the urogenital or anorectal flora may be altered by
chemotherapeutic agents that are used in the treatment and prophylaxis of genitourinary or intestinal infections. The flora frequently develop antibiotic resistance and cause a
reinfection or primary opportunistic infection. Such infections may be a consequence of the eradication of normal, harmless flora, such as lactobacilli, allowing other pathogenic
microbes, resistant to the antibiotics, to.flourish.
Studies have revealed that low levels of secretory IgA (slgA) in urine indicate a
defective local immune response of the urinary tract and favor urogenital tract infections. An important property of slgA is the prevention of interaction of bacterial pili or outer membrane
constituents of viruses or other microbes with the specific receptors found on the epithelium
of the vaginal anorectal mucosa or urinary tract. Pili-mediated adhesiveness is an important
virulence factor of the bacteria involved. In the case of viruses and non-piliated microbes, other outer membrane constituents are involved in host-attachment phenomena, prior to propagation
to infection. For the defense against infection it is important to reduce the adhesion of the
pathogens to the epithelium or to prevent the attachment of the pathogen altogether.
Normally, the host organism forms specific local antibodies against the invading bacteria
and secretes these antibodies as slgA. In patients with persisting or frequently relapsing urinary tract infections this natural mechanism of local immuno logical infection defense is apparently
disturbed. Therefore, enhancement of immune defense is a rational means of eliminating the
cause of recurrent urinary tract infections.
A vaccination strategy that stimulates the production of antibodies to a spectrum of antigens that are present in several types of pathogens is desirable. Vaccination of the urogenital
or anorectal epithelium with nucleic acids encoding specific proteins involved in pathogen-host
attachment phenomena presents a novel method of stimulating cell-mediated immunity.
Previously, vaccines against urogenital infections have been administered parenterally
or orally and have resulted in enhanced resistance to urogenital infections. However, patients suffer from side effects such as malaise, fever, and muscle soreness. Oral vaccines are subject
to the destructive influences of gastric acidity and digestive enzymes. A necessary retention at
a local surface for extended transmucosal contact may be difficult to achieve. Prior art
concerning mucosal vaccination through the vaginal route using whole cell lysates has taught enhanced resistance to recurrent infection, but there is no mention of transmucosal immunization
by the anorectal route and the production of transmucosal immunity against local infection at the
site of delivery system target. No specifically therapeutic local immune response to a delivery
system is presented. The efficacy presented is confined to non-specific vaccine materials that
present a complex potential to produce complex reactions by poorly understood mechanisms.
In an attempt to overcome the defects associated with parenteral and oral administrations
of vaccines or in using vaginally-delivered vaccines comprised of fractionated or whole cell extracts, an intravaginal or intrarectal mucosal vaccine delivery system against infections is
proposed wherein the vaccine is comprised of purified antigenic determinants capable of
stimulating an immune response to pathogenic factors involved in attachment and disease.
Administering a vaccine against urogenital or anorectal infections intravaginally or intrarectally
is that there is a mucosal immune system wherein antigens are absorbed through mucosal
surfaces and processed by specialized local lymphoid tissues, after which antibodies are secreted onto local mucosal surfaces. In the case of nucleotide vaccines, epithelial cells of the mucosa
express the proteins to the cell surface promoting cellular-mediated immune responses. As
discussed above, in the genitourinary tract, temporary or partial deficiencies in local vaginal or
urinary antibodies are an important factor in the heightened susceptibility to urogenital infections shown in some women. Immunization via the mucosal surfaces within the genitourinary tract
is preferable to parental or oral routes as it has been discovered that vaccination via the
intravaginal surface creates a secretory immune response in the urogenital tract. With nucleotide
vaccines, such vaccination stimulates specific cellular-mediated immune responses.
Advances in the identification of specific pathogenic factors involved in infection
attachment and propagation, the elucidation of the mucosal immune system and the ability of the
mucosal tissue to participate in cellular-mediated immune response via nucleotide vaccination
suggest that vaccination of the genitourinary/anorectal tract by a transvaginal or anal route is
preferable to oral or parenteral immunization. The specific method of vaginal or rectal
immunization may actually resolve infection before disease ensues, preventing pathogen
attachment or neutralizing toxins prior to pathogen and host interaction.
For instance, in the past, urinary tract infections vaccines were administered vaginally
in the form of a liquid vaccine. Several problems were associated with the intravaginal
administration of liquid urinary tract infections vaccine. The major problem encountered was
that the liquid vaccine flowed out of the vagina soon after insertion. This severely limits the amount of time that the liquid antigens are in contact with the mucosal surface of the vagina,
decreasing the effectiveness of the vaccine. The antigens need sufficient contact with the vaginal mucous membrane to elicit a secretory immunoglobin response. Patients receiving the
vaccination were required to lie in a supine position for an extended time after receiving the
vaccine to prevent the vaccine from immediately flowing out of the vagina. However, often the
vaccine still leaked out of the vagina following the period of time in the supine position, limiting the effectiveness of the vaccine. In addition, the requirement that patients lie in a supine position
for an extended time after receiving the vaccine, is a burden on the patient. Patients may receive
several vaccinations over the course of treatment and the patients must spend a considerable amount of time after each vaccination immobile.
USSN 08/923,813 entitled Vaginal Suppository Vaccine For Urogenital Infections was
filed 9/4/97 and allowed. This application is owned by assignee herein and relates to a suppository based vaccine delivery system for immunizing against urogenital infectious diseases
in humans.
It is apparent that improvements are necessary in optimizing vaccine delivery to the
urogenital mucosa for effective prophylaxis against urogenital infectious diseases. Further, it is
desirable to have a rectally-administered vaccine for effective prophylaxis against rectal tract infections involving transmission through the anorectal tract.
The subject invention overcomes the above limitations and others, and teaches a
suppository-based vaccine delivery system for prophylaxis against urogenital and anorectal tract
infectious diseases, such as bacterial, protozoal, fungi, viral infections and the like, using
fractionated, whole cell or purified protein, nucleic acid or lipid constituents, whether native,
mutated, synthetic, cloned or recombinantly expressed, of urogenital anorectal pathogens that stimulate the generation of humoral or cellular-mediated immune response.
Summary of the Invention
According to the present invention, there is provided an intravaginally or intrarectally
administered suppository based vaccine delivery system for prophylaxis against urogenital or anorectal localized or transmitted infectious diseases.
Further according to the present invention, there is provided a suppository based vaccine delivery system for the prophylaxis against or treatment of urogenitally or rectally transmitted
or localized infectious diseases, such as bacterial, protozoal, fungal or viral infections wherein
the vaccine or vaccine adjuvant is in contact with the vaginal or anorectal mucous membrane for a sufficient period of time to enhance the immune response.
Still further according to the present invention, there is provided a suppository based
vaccine delivery system for the prophylaxis against or treatment of urogenitally or rectally
transmitted or localized infectious diseases, such as bacterial, protozoal, fungal or viral
infections, wherein the vaccine or vaccine adjuvant is easily administered, does not require the
patient to lie in a supine position for an extended period of time after receiving the vaccination, and is suitably administered by the patient for primary and routine booster requirements.
Still further according to the present invention, there is provided a suppository based
vaccine delivery system for prophylaxis against urogenitally or rectally transmitted or localized
infectious diseases, such as bacterial, protozoal, fungal or viral infections in humans or animals, said suppository comprising: a vaccine or vaccine adjuvant containing whole or fractionated
viral or other microbial pathogens, or their purified cellular constituents, whether native, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, lipids or
other antigenic determinants capable of producing humoral- or cellular-mediated immunity in
humans or animals, wherein the suppository is comprised of a suitable base that liquefies or becomes water miscible at body temperature in order to deliver vaccine components to the
urogenital or anorectal mucosa; wherein the suppository is adapted to be inserted vaginally or rectally so as to allow the suppository to be in contact with mucous membrane to facilitate
transfer of vaccine or vaccine adjuvant material therethrough.
An advantage of the present invention is the provision of a suppository based vaccine
delivery system for the prophylaxis against or treatment of urogenital and/or rectally transmitted
or localized infectious diseases, such as viral or other pathogenic microbial infections, wherein the vaccine or vaccine adjuvant is in contact with the vaginal or rectal mucous membrane for a
sufficient period of time to enhance the immune response.
Another advantage of the present invention is the provision of a suppository based
vaccine delivery system wherein humoral- and/or cell-mediated stimulation from mucosal
vaccination allows immune responses to specifically keep viral or microbial shedding or
colonization from occurring or recurring, or prohibiting pathogen-host attachment instead of
fighting the infection after it has colonized or has propagated.
Another advantage of the present invention is the provision of a suppository based
vaccine delivery system wherein the suppository can be easily manufactured to allow
incorporation of vaccine or vaccine adjuvant(s) with preservatives, such as thimersal; is a solid at or below room temperature for structure and to allow ease of insertion; and becomes liquified or water-miscible at body temperature so as to allow its components to enhance an immune
response.
Another advantage of the present invention is the provision of a suppository based
vaccine delivery system for the prophylaxis against urogenitally or rectally transmitted or localized infectious diseases, such as viral or other pathogenic microorganism infections,
wherein the vaccine is easily administered, and does not require the patient to be in a supine
position for an extended period of time after receiving the vaccination.
Another advantage of the present invention is the provision of a suppository based
vaccine delivery system wherein the vaccine can be readily self-administered by the patient.
Another advantage of the present invention is the provision of a suppository based
vaccine delivery system wherein the administration of the vaccine is relatively painless.
Yet another advantage of the present invention is the provision of a suppository based vaccine delivery system wherein the patient may self-administer booster vaccinations
periodically.
Still other advantages of the invention will become apparent to those skilled in the art upon a
reading and understanding of the following detailed description, and appended claims.
Detailed Description of the Preferred Embodiment
This invention is directed to a suppository based vaccine delivery system for immunizing
against infectious disease in humans and animals and a method for treating the same. More
particularly, this invention is directed to a suppository based vaccine delivery system for the
prophylaxis against or treatment of urogenitally and anorectally localized or transmitted infectious diseases, such as from viral or other pathogenic microbial infections including but not
limited to bacteria, protozoans, fungi and the like. The suppository based vaccine delivery
system comprises a vaccine and/or vaccine adjuvant(s) comprising pathogenic microbial or viral
antigenic constituents and optionally a preservative and optionally a buffer; wherein the suppository is adapted to be inserted into a bodily orifice of a human or animal so as to allow the
vaccine and/or vaccine adjuvant to come in contact with the mucosal tissue of the bodily orifice to facilitate transfer of the suppository material therethrough.
The suppository comprises a vaccine and/or vaccine adjuvant(s) comprising fractionated
or whole cell or purified cellular constituents whether native, mutated, synthetic, cloned or
recombinantly-expressed pathogenic microbial or viral protein lipids or nucleic acid constituents
that are capable of stimulating humoral- or cellular-mediated immune responses against which
the pathogens or constituents correspond.
The suppository comprises a vaccine and/or vaccine adjuvant(s) that is prepared by either purifying native pathogen constituents, by synthesis or recombinant expression of protein or genetic components of native pathogens or by purifying synthetic, mutated or cloned pathogen-
derived nucleic acid sequences.
The suppository of the present invention comprises any suitable suppository base known in the art. More particularly, the suppository base comprises material that is solid or semi-solid
at or below room temperature but liquefies or becomes water-miscible at body temperature. The
suppository base includes but is not limited to polyethylene glycol, triglycerides, fatty acids,
fatty alcohols, glycerin and the like. Preferably the suppository base is polyethylene glycol. The
suppository base optionally includes emulsifying agents such as polysorbate, gelatin,
methylcellulose, alginic acid, sodium lauryl sulfate, and the like.
The suppository base is present in the delivery system in any suitable amount so as to allow the incorporation of the vaccine or vaccine adjuvant(s) in a solid or semi-solid form so that
the structural integrity is maintained or that insertion into a body orifice can be easily performed.
When inserted, the suppository base liquefies or becomes water-miscible at body temperature
so as to allow the vaccine and/or vaccine adjuvant components to become in contact with the
mucous membrane for a sufficient period of time to enhance the immune response. The weight
percent of the suppository base is dependent upon the size of the bodily orifice of the human and/or the animal, the dosage of vaccine and/or vaccine adjuvant(s) necessary to elicit an immune response and its physiochemical characteristics that allow it to remain solid at or below
room temperature. The suppository comprises from about 50% to greater than 99%, preferably
about 75%o to greater than 99% by weight of the suppository base. Preferably the suppository comprises about 75% to about 98% by weight polyethylene glycol. Preferably the suppository
comprises about 2% to about 25% by weight polysorbate. The suppository base has a molecular weight in the range of about 400 to about 5000, preferably about 950 to about 3700. In a more
preferred embodiment, the polyethylene glycol suppository base is comprised of about 39% by weight of polyethylene glycol having a molecular weight of about (3000) and about 59% by
weight of polyethylene glycol having a molecular weight of about 400. A suitable commercially
available polyethylene glycol suppository base is POLYBASE, available from Paddock Laboratories, Inc.
The suppository base optionally includes either or both of a preservative(s) and a
buffer(s). The preservative is selected from the group consisting of thimersal, benzoic acid,
benzoic acid derivatives, benzylkonium, benzylkonium chloride sulfites, quaternary ammonium
salts, chloro-butanol and combinations thereof at concentrations ranging from about 0.01% to about 0.5%). The buffers are employed so that the pH of the suppository vaccine remains the
same. The buffers used are those known in the art and include, but are not limited to citrate,
phosphate, hepes (or their salts) and combinations thereof at a concentration in the range of
about 5 milimolar to about 0.5 molar.
The suppository base confers a degree of miscibleness with the mucous membrane surfaces of the vagina or rectum, wherein suspended particles of the vaccine and/or vaccine
adjuvant(s) are in contact with such mucous membrane surfaces for a sufficient amount of time
to elicit a humoral- or cell-mediated immune response. The suppository base has an adjuvant
effect that enhances the immune response by allowing the vaccine to facilitate contact time with the vaginal or anorectal tract mucous membranes, serving as a depot that slowly releases antigen,
and by localizing and delivering antigens to immunocompetent cells. The suppository base
possesses properties that allow the suppository to be molded in a desirable form and further
function as a structural necessity that keeps the suppository in its desired molded form at or below room temperature.
The suppository is allowed to harden in a suppository shell or a mold that forms the
desired shape. The suppository is generally stored in the shell until used or is removed from the
mold and repackaged. The suppository shell or mold is any shell or mold known in the art
suitable for molding or packaging of the suppository. A suitable commercially available
laminate suppository shell is a polyvinylchloride polyethylene laminate suppository shell
available from Paddock Laboratories, Inc.
The suppository based vaccine delivery system of the present invention is prepared
by general techniques known in the art. Typically, the suppository base vaccine delivery
system is prepared under a sterile environment. The suppository base is heated in a sterile environment to a temperature in the range of its melting point to liquefy the base. The suppository base is heated for a time sufficient to liquefy it without degrading it.
The vaccine or vaccine adjuvant(s) comprising the whole or fractionated viral or other
microbial pathogen, or their purified cellular constituents or derivatives, whether native,
mutated, synthetic, cloned or recombinantly expressed, that consist of nucleic acids, proteins,
lipids or other antigenic determinants capable of producing humoral-or cullular-mediated immunity is placed in a container containing the liquified suppository base. The vaccine
and/or vaccine adjuvant(s) are stirred with the liquid suppository base until a homogeneous
suspension is produced. A preservative or adjuvant is added and stirred until a homogeneous
suspension is again attained. The suspension comprising the suppository base and the vaccine and/or vaccine adjuvant(s) and preservative is placed into individual laminate
suppository shells. The suppository is then cooled at room temperature to allow it to harden.
The suppositories are then heat-sealed and stored at refrigerated temperature.
The suppository based vaccine delivery system according to the present invention
when inserted into a bodily orifice and allowed to liquify or become water-miscible allows the vaccine to be in contact with the vaginal or rectal tract mucous membrane for a sufficient
period of time to enhance the immune response. Further, the suppository based vaccine
delivery system according to the present invention allows the incorporation of vaccine,
■vaccine adjuvant(s) and preservative and is easily administered, does not require the patient to lie in a supine position for an extended period of time after receiving the vaccination, is
suitably administered by the patient, is painless, is amenable to routine booster vaccinations
and allows a favorable method of antigen delivery to immunocompetent cells through the
mucosa.
The present invention is further exemplified in the following example. The example
illustrates the effectiveness of the suppository based vaccine delivery system of the present
invention. It is understood that the example is only illustrative of preferred embodiments
according to the present invention wherein the claims set forth the scope of the present invention.
EXAMPLE
In this example, the HSV-2 gD2 and its complementary DNA are used as
representative vaccine candidates for mucosal immunization. This protein is specific to the herpes simplex-2 (HSV-2) virus and represents a major outer membrane constituent of the
virus that is implicated in the host-attachment phenomena. Others have demonstrated that
this protein is a candidate vaccine to prevent transmission or recurrence of HSV-2. This is
based on its antigenicity and, that following parenteral vaccination, it elicits satisfactory
immune response based on protection against HSV-2 challenge in animal models. The DNA of HSV-2 gD2 is the cloned complementary DNA encoding this protein. Its use as a DNA
vaccine is intended to stimulate the production of cellular-mediated immune response. Both
the protein and cDNA is manufactured by Protein Express, Inc., Cincinnati, Ohio.
POLYBASE, a polyethylene glycol polysorbate suppository base manufactured by
and available from Paddock Laboratories, Inc., in an amount sufficient to manufacture 50
■two-gram suppositories, was heated in a sterile flask atop a magnetic stirrer/heater to a temperature of about 60°C for about one hour to liquefy the suppository base. Recombinant
HSV gD2 protein and/or its complementary DNA, 500 micrograms each (enough to
manufacture about 50 suppositories) was aseptically placed in the liquefied suppository base
suppository. A sterile magnetic stir bar was placed in the flask, and the vaccine and
suppository base were stirred for about 10 minutes at about 60°C in a temperature-controlled
water bath to form a homogeneous suspension. Thimersal, as a preservative, was added to a final concentration of about 0.1% and stirred until a homogeneous suspension was
achieved. The suspension comprised of the suppository base, the vaccine and the
preservative was then placed into individual polyvinyl chloride-polyethylene laminate suppository shell using a sterile pipette. Approximately 2.0 ml of the suspension was placed
into each shell.
The suppository base was cooled at a temperature of about 24°C for about 30 minutes
to harden the suppository base. The top of each shell was heat-sealed and the suppositories
were then stored at about 4°C. When used, the suppositories are removed from the shell and inserted vaginally or rectally.
While various embodiments of a suppository based vaccine delivery system for
treating or prophylaxes against urogenitally and/or anorectally transmitted or localized
infectious diseases and a method for treating or prophylaxes against urogenitally and/or
anorectally transmitted infections in humans and animals have been disclosed, it should be understood that modifications and adaptations thereof will occur to persons skilled in the art.
Other features and aspects of this invention will be appreciated by those skilled in the art
upon reading and comprehending this disclosure. Such features, aspects, and variations and
modifications of the reported results and examples are clearly within the scope of the
invention where the invention is limited solely by the scope of the following claims.
Claims (20)
1. A suppository based vaccine delivery system for prophylaxis against or
treatment of urogenitally and anorectally transmitted infectious disease in humans and animals, said suppository comprising:
(a) a vaccine or vaccine adjuvant(s) selected from the group consisting
of whole or fractionated viral or other microbial pathogens, or their purified cellular
constituents, whether native, mutated, synthetic, cloned or recombinantly-expressed and
combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic
determinants or combinations thereof capable of producing humoral- or cellular-mediated immunity in humans or animals; and
(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;
wherein the suppository is adapted to be inserted into a bodily orifice of a human or animal so as to allow the suppository to be in contact with tissue of the bodily
orifice to facilitate transfer of suppository material therethrough.
2. A suppository based vaccine delivery system for prophylaxis against
urogenital tract infections in humans, said suppository comprising:
(a) a vaccine or vaccine adjuvant(s) selected from the group consisting of whole or fractionated viral or other microbial pathogens, or their purified cellular
constituents, whether native, mutated, synthetic, cloned or recombinantly-expressed and
combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic
determinants or combinations thereof capable of producing humoral or cellular-mediated
immunity in humans; and (b) a suppository base, selected from the group consisting of polyethylene
glycol, polysorbate and combinations thereof;
wherein the suppository is adapted to be inserted vaginally so as to allow the
suppository to be in contact with vaginal mucous membrane to facilitate transfer of
suppository material therethrough.
3. A suppository based vaccine delivery system for prophylaxis against
anorectally transmitted infectious disease in humans or animals, said suppository comprising:
(a) a vaccine or vaccine adjuvant(s) elected from the group consisting of
whole or fractionated viral or other microbial pathogens, or their purified cellular
constituents, whether native, mutated, synthetic, cloned or recombinantly expressed and
combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated
immunity in humans or animals; and
(b) suppository base, selected from the group consisting of polyethylene
glycol, polysorbate and combinations thereof; wherein the suppository is adapted to be inserted rectally so as to allow the
suppository to be in contact with the anorectal mucous membrane to facilitate transfer of
vaccine or vaccine adjuvant material therethrough.
4. The suppository based vaccine delivery system of claim 1 wherein the vaccine content or vaccine adjuvant(s) is selected from the group consisting of whole cells, purified
constituents or is generated from known genetic information of urogenital or anorectally
transmittable pathogens.
5. The suppository based vaccine delivery system of claim 1 wherein the vaccine
or vaccine adjuvant(s) contents are present in the total amount of 10 to 1000 micrograms.
6. The suppository based vaccine delivery system of claim 1 wherein the
suppository base is comprised of polyethylene glycol and polysorbate.
7. The suppository based vaccine delivery system of claim 6 wherein the
polyethylene glycol suppository base is comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate.
8. The suppository based vaccine delivery system of claim 6 wherein the
polyethylene glycol has an average molecular weight of about 950 to about 3700.
9. The suppository based vaccine delivery system of claim 6 wherein the
polyethylene glycol suppository base comprises from about 70% to greater than 99% by
weight of the suppository.
10. The suppository based vaccine delivery system of claim 1 wherein the
suppository is further comprised of a preservative selected from the group consisting of thimersal, benzoic acid, benzylkonium, benzylkonium chloride, sulfites, quaternary
ammonium salts, chlorobutanol and combinations thereof.
11. The suppository based vaccine delivery system of claim 10 wherein the
suppository is further comprised of an emulsifying agent selected from the group consisting
of gelatin, methyl cellulose, alginic acid, sodium lauryl sulfate and combinations thereof.
12. A suppository-based vaccine delivery system for prophylaxis against urogenital or anorectally transmitted infections in humans or animals, said suppository comprising:
(a) a vaccine or vaccine adjuvant(s) comprising purified, mutated,
synthetic or genetically engineered constituents of known pathogens selected from the group
consisting of urogenital pathogens, anorectally pathogens and combinations thereof; and
(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;
wherein the polyethylene glycol suppository base is comprised of about 75% to about
98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 950 to about 3700,
and wherein the polyethylene glycol suppository base comprises from about 70% to about
99% by weight of the suppository; wherein the suppository is adapted to be inserted vaginally
or rectally so as to allow the suppository to be in contact with mucous membrane to facilitate
transfer of vaccine or vaccine adjuvant(s) material therethrough.
13. A suppository-based vaccine delivery system for prophylaxis against genitourinary or anorectal tract infections in humans or animals, said suppository resulting
from the mixture of:
(a) a vaccine or vaccine adjuvant selected from the group consisting of
whole or fractionated viral or other microbial pathogens, or their purified cellular
constituents, whether native, mutated, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations
thereof capable of producing humoral or cellular-mediated immunity in humans or animals;
and
(b) a suppository base, selected from the group consisting of polyethylene
glycol, polysorbate and combinations thereof;
wherein the polyethylene glycol suppository base is comprised of about 75% to about
98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 750 to about 3700,
and wherein the polyethylene glycol suppository base comprises from about 70% to greater
than 99% by weight of the suppository base; wherein the suppository is adapted to be inserted
vaginally or rectally so as to allow the suppository to be in contact with mucous membrane
to facilitate transfer of vaccine or vaccine adjuvant(s) material therethrough.
14. A method for preventing urogenital or anorectal disease in humans or animals,
said method comprising the steps of:
(a) inserting a suppository-based vaccine delivery system into a bodily orifice of a human, wherein said suppository comprises a vaccine or vaccine adjuvant(s) material comprised of whole, fractionated viral or other microbial pathogens, or their purified ' cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed,
that consists of nucleic acids, proteins, other antigenic determinants or combinations thereof
capable of producing humoral or cellular-mediated immunity in humans or animals; and
(b) contacting the suppository with mucosal tissue at and internal to the
bodily orifice to facilitate transfer of the vaccine or vaccine adjuvant material therethrough
and induce an immune response in the human.
15. The method of claim 14 wherein the protein or nucleic acid originate from the
genetic constituents of pathogenic urogenital or anorectally transmissible viruses, other microbes or combination thereof.
16. The method of claim 14 wherein the amount of protein, nucleic acids, lipids, other antigenic determinants and combinations thereof are present in the total amount of
about 10 to about 1000 micrograms.
17. The method of claim 14 wherein the polyethylene glycol suppository base is selected from the group consisting of polyethylene glycol, polysorbate and combination
thereof.
18. The method of claim 17 wherein the polyethylene glycol suppository base is
comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about
25% by weight polysorbate.
19. The method of claim 18 wherein the polyethylene glycol has an average
molecular weight of about 750 to about 3700.
20. The method of claim 14 wherein the suppository base comprises from about
80% to greater than 99% by weight of the suppository base.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09516078 | 2000-03-01 | ||
| US09/516,078 US7135191B2 (en) | 1997-09-04 | 2000-03-01 | Urogenital or anorectal transmucosal vaccine delivery system |
| PCT/US2001/006221 WO2001064186A1 (en) | 2000-03-01 | 2001-02-27 | Urogenital or anorectal transmucosal vaccine delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001241802A1 true AU2001241802A1 (en) | 2001-09-12 |
Family
ID=24054035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001241802A Abandoned AU2001241802A1 (en) | 2000-03-01 | 2001-02-27 | Urogenital or anorectal transmucosal vaccine delivery system |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7135191B2 (en) |
| EP (1) | EP1263410A1 (en) |
| JP (1) | JP2003525230A (en) |
| CN (1) | CN1427715A (en) |
| AU (1) | AU2001241802A1 (en) |
| BR (1) | BR0109034A (en) |
| CA (1) | CA2401804A1 (en) |
| EA (1) | EA200200931A1 (en) |
| MX (1) | MXPA02008492A (en) |
| WO (1) | WO2001064186A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135191B2 (en) * | 1997-09-04 | 2006-11-14 | Zsolt Istvan Hertelendy | Urogenital or anorectal transmucosal vaccine delivery system |
| CZ2004964A3 (en) * | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Peroral pharmaceutical composition for targeted transport of platinum complex into colorectal region, process for its preparation and the composition for use as medicament |
| US20110229512A1 (en) * | 2010-03-19 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating urinary tract infections |
| WO2013136185A2 (en) | 2012-03-13 | 2013-09-19 | Becton Dickinson France | Method of manufacture for a miniaturized drug delivery device |
| CA3120699A1 (en) | 2018-11-21 | 2020-05-28 | Endomet Biosciences, Inc. | Compositions and methods for treating endometriosis |
| CN114366808B (en) * | 2021-12-14 | 2023-10-13 | 南京农业大学 | Polysaccharide and virus antigen co-delivery nano vaccine, and preparation method and application thereof |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2975099A (en) * | 1958-06-25 | 1961-03-14 | Upjohn Co | Polyethylene glycol suppository bases |
| US3551554A (en) * | 1968-08-16 | 1970-12-29 | Crown Zellerbach Corp | Enhancing tissue penetration of physiologically active agents with dmso |
| US3880991A (en) * | 1969-03-24 | 1975-04-29 | Brook David E | Polymeric article for dispensing drugs |
| DK127268A (en) * | 1970-01-12 | 1900-01-01 | ||
| US3711602A (en) * | 1970-10-30 | 1973-01-16 | Crown Zellerbach Corp | Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso |
| US3773929A (en) * | 1972-11-02 | 1973-11-20 | Diagnostic Data Inc | Pharmaceutical compositions comprising orgotein and their use |
| US3776001A (en) * | 1973-01-16 | 1973-12-04 | Kimberly Clark Co | Self-lubricating compound for use in hygienic and medical applications, and suppositories made therefrom |
| JPS5492914A (en) * | 1977-12-28 | 1979-07-23 | Kondo Shigeji | Novel peptide antibiotic substance and its manufacture |
| US4756907A (en) * | 1978-10-17 | 1988-07-12 | Stolle Research & Development Corp. | Active/passive immunization of the internal female reproductive organs |
| JPS6030650B2 (en) * | 1979-10-26 | 1985-07-17 | 日本油脂株式会社 | Suppository base composition |
| EP0037943B1 (en) * | 1980-03-31 | 1985-08-14 | Teijin Limited | Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom |
| US4404144A (en) * | 1981-02-20 | 1983-09-13 | G. D. Searle & Co. | Unsaturated analogs of β-alkyl-β-hydroxy glutaric acid and esters thereof |
| US4360593A (en) * | 1981-04-03 | 1982-11-23 | Bristol-Myers Company | Process of producing a peptide antibiotic with Bacillus circulans |
| US4439194A (en) * | 1981-09-08 | 1984-03-27 | Merck & Co., Inc. | Water and drug delivery system for suppository use |
| US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
| JPS58152809A (en) * | 1982-03-05 | 1983-09-10 | Eisai Co Ltd | Stable foaming vaginal suppository |
| US4698359A (en) * | 1982-08-24 | 1987-10-06 | Cilag, Ag | Medicated suppository |
| US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
| CH664497A5 (en) | 1984-08-31 | 1988-03-15 | Solco Basel Ag | VACCINE FOR TREATING UTILITY INFECTION. |
| JPS62502262A (en) * | 1985-03-27 | 1987-09-03 | ブロンコスタット・プロプライアタリー・リミテツド | Vaccines without adjuvants |
| US4820698A (en) | 1985-11-04 | 1989-04-11 | The Procter & Gamble Company | Antimicrobial agents and process for their manufacture |
| US4939284A (en) | 1985-11-04 | 1990-07-03 | The Procter & Gamble Company | Process for the manufacture of tetraalkyl ethenylidenebisphosphonate esters |
| US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| US4863900A (en) * | 1987-01-15 | 1989-09-05 | The Research Foundation Of State University Of New York | Method for reducing viral transmission with poly-L-histidine |
| US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
| IT1231410B (en) * | 1987-09-22 | 1991-12-04 | Cooperativa Farmaceutica | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION WITH PROLONGED EFFECT FOR TOPICAL USE |
| HU203204B (en) * | 1987-09-15 | 1991-06-28 | Sandoz Ag | Process for producing suppository containing calcitonin and taurocholic acid |
| US5270344A (en) * | 1988-06-24 | 1993-12-14 | Stephen Herman | Method of treating a systemic disorder using trioxolane and diperoxide compounds |
| US5364879A (en) | 1988-06-24 | 1994-11-15 | Cliveden Ltd. | Medical uses of trioxolane and diperoxide compounds |
| US5057523A (en) | 1988-09-22 | 1991-10-15 | Abbott Laboratories | Dipeptide quinolone derivatives |
| US5057520A (en) | 1989-03-24 | 1991-10-15 | Abbott Laboratories | 7-(peptidylpyrolidinyl)naphthyridine antibacterial compounds |
| US5002771A (en) * | 1989-02-06 | 1991-03-26 | Rorer Pharmaceutical Corp. | Calcitonin suppository formulations |
| US5849531A (en) * | 1989-04-07 | 1998-12-15 | University Of Saskatchewan | Compositions and treatments for pneumonia in animals |
| CA2014033C (en) * | 1989-04-07 | 1993-02-09 | Stephen D. Acres | Compositions and treatments for pneumonia in animals |
| US5096940A (en) * | 1989-06-07 | 1992-03-17 | Techmer Pm | Degradable polymeric compositions |
| US5189066A (en) * | 1989-11-22 | 1993-02-23 | The Procter & Gamble Company | Pharmaceutical compositions of tebufelone |
| FR2662942B1 (en) * | 1990-06-06 | 1992-09-18 | Neway Tsehay | IMMUNOSTIMULATING MEDICINE BASED ON POLAR GLYCOPEPTIDOLIPIDES OF MYCOBACTERIUM CHELONAE. |
| IT1243379B (en) * | 1990-07-27 | 1994-06-10 | Giuliani Spa | PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL |
| US5594107A (en) * | 1990-08-22 | 1997-01-14 | University Of Saskatchewan | Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon |
| IT1243390B (en) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION. |
| US5234914A (en) * | 1991-06-11 | 1993-08-10 | Patent Biopharmaceutics, Inc. | Methods of treating hemorrhoids and anorecial disease |
| US5629012A (en) * | 1991-06-17 | 1997-05-13 | Farmaceutisk Laboratorium Ferring A/S | Process for producing suppositories by compression and suppositories obtained by the process |
| US5417971A (en) * | 1991-10-22 | 1995-05-23 | University Of Saskatchewan | Vaccines for Actinobacillus pleuropneumoniae |
| GB2261372A (en) * | 1991-11-15 | 1993-05-19 | Gregor Reid | Lactobacillus and skim milk compositions for prevention of urogenital infection |
| US5686268A (en) * | 1992-06-19 | 1997-11-11 | Pfizer Inc. | Fused proteins |
| US5534256A (en) * | 1992-07-02 | 1996-07-09 | University Of Saskatchewan | Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins |
| US5667782A (en) * | 1992-07-16 | 1997-09-16 | Oxford University | Multiple particulate antigen delivery system |
| US5441736A (en) * | 1992-11-05 | 1995-08-15 | University Of Saskatchewan | Actinobacillus pleuropneumoniae outer membrane lipoprotein A and uses thereof |
| US6660484B2 (en) * | 1992-11-13 | 2003-12-09 | Regents Of The University Of California | Colorimetric glycopolythiophene biosensors |
| CA2155947C (en) * | 1993-02-22 | 2007-08-21 | Mark W. Grinstaff | Methods for in vivo delivery of biologics and compositions useful therefor |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5840318A (en) * | 1993-05-11 | 1998-11-24 | Immunom Technologies, Inc. | Methods and compositions for modulating immune systems of animals |
| US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5766632A (en) * | 1993-10-01 | 1998-06-16 | Legere Pharmaceuticals, Ltd. | Method of using lectins for contraception |
| US6159174A (en) * | 1993-10-01 | 2000-12-12 | Legere Pharmaceuticals, Ltd. | Method of using lectins for therapy of diseases transmittable by sexual contact |
| AU8087994A (en) * | 1993-10-26 | 1995-05-22 | Syntello Inc. | Inhibition of hiv mucosal infection |
| UA39965C2 (en) * | 1993-12-03 | 2001-07-16 | Лайфор Леборетріз Лтд | VIRUSIC, BACTERICIDAL AND DESTRUCTIVE SPERMATOSES VAGINAL PRODUCT AND VAGINAL SUPPOSITORY (OPTIONS) |
| US5733568A (en) * | 1993-12-03 | 1998-03-31 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
| US5820868A (en) * | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
| US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| HU215443B (en) * | 1994-07-25 | 1999-04-28 | Márton Milánkovits | Pharmaceutical compositions, first of all vaginal suppositorium, containing more active components with bactericide, fungicide, antiprotozoonic and antiviral combined activity |
| AUPM747694A0 (en) * | 1994-08-16 | 1994-09-08 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids and peptides |
| GB9417880D0 (en) * | 1994-09-06 | 1994-10-26 | Auspharm Int Ltd | Vaccine |
| GB9420146D0 (en) * | 1994-10-06 | 1994-11-23 | Cancer Res Campaign Tech | Papillomavirus vaccine |
| US5776921A (en) * | 1994-10-20 | 1998-07-07 | Gates; Stephen | Compositions for regulation of immune responses |
| FR2728265A1 (en) * | 1994-12-19 | 1996-06-21 | Oreal | USE OF A SUBSTANCE P ANTAGONIST IN A PHARMACEUTICAL COMPOSITION |
| WO1996020703A1 (en) * | 1995-01-06 | 1996-07-11 | Australian Biomedical Company Pty. Ltd. | Compounds for veterinary and medicinal applications |
| US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| US5681552A (en) * | 1995-05-23 | 1997-10-28 | The Mennen Company | Clear cosmetic stick composition containing a combination of anionic and non-ionic surfactants |
| US5863543A (en) * | 1996-06-05 | 1999-01-26 | University Of Saskatchewan | Camp factor of streptococcus uberis |
| US5654174A (en) * | 1995-07-07 | 1997-08-05 | Competitive Technologies, Inc. | Herpes simplex virus glycoprotein D variants |
| GB9514285D0 (en) * | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
| EP0839029A1 (en) * | 1995-07-20 | 1998-05-06 | PHARMACIA & UPJOHN COMPANY | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
| AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
| US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US5783194A (en) * | 1996-01-30 | 1998-07-21 | University Of Ottawa | Homogeneous isolate of urabe mumps virus and vaccines containing the isolate |
| US6576633B1 (en) * | 1996-02-22 | 2003-06-10 | The Dow Chemical Company | Stable liquid antimicrobial suspension compositions containing quarternaries prepared from hexamethylenetetramine and certain halohydrocarbons |
| US6750216B2 (en) * | 1996-03-08 | 2004-06-15 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| US6218147B1 (en) * | 1996-07-26 | 2001-04-17 | Hsc Research & Development Limited Partnership | Haemophilus adhesin protein |
| US6251433B1 (en) * | 1996-08-13 | 2001-06-26 | Chiron Corporation | Polycationic polymers |
| US5908845A (en) * | 1996-10-30 | 1999-06-01 | Segev; David | Polyether nucleic acids |
| US5853767A (en) * | 1997-01-02 | 1998-12-29 | Melman; Steven A. | Compositions for treating fungal, parasitic and/or bacterial infections, especially infections of organs such as the skin and vagina |
| IN186803B (en) * | 1997-02-05 | 2001-11-10 | Panacea Biotec Ltd | |
| JPH10265380A (en) * | 1997-03-17 | 1998-10-06 | Bristol Myers Squibb Co | Anticancer agent |
| US6569426B2 (en) * | 1997-04-03 | 2003-05-27 | Genzyme Corporation | Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity |
| IL132164A0 (en) * | 1997-04-09 | 2001-03-19 | Chang Lung Ji | Animal model for evaluation of vaccines |
| US6211159B1 (en) * | 1997-04-11 | 2001-04-03 | University Of Toronto | Flagellin gene, FlaC of campylobacter |
| EP0975370B9 (en) * | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| EP0984790A1 (en) * | 1997-06-02 | 2000-03-15 | Chiron Corporation | Herpes simplex virus vp22 vaccines and methods of use |
| US20030044434A1 (en) * | 1997-07-29 | 2003-03-06 | Ping Gao | Self-emulsifying formulation for lipophilic compounds |
| CA2294032A1 (en) * | 1997-07-29 | 1999-02-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
| US7135191B2 (en) * | 1997-09-04 | 2006-11-14 | Zsolt Istvan Hertelendy | Urogenital or anorectal transmucosal vaccine delivery system |
| US6099853A (en) * | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| US6046179A (en) * | 1998-04-17 | 2000-04-04 | Murch; Simon | Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine |
| WO1999058726A1 (en) * | 1998-05-12 | 1999-11-18 | Genecure Llc | Replication defective hiv vaccine |
| AU4228699A (en) * | 1998-06-03 | 1999-12-20 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
| US6200590B1 (en) * | 1998-08-10 | 2001-03-13 | Naphcare, Inc. | Controlled, phased-release suppository and its method of production |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US6348583B1 (en) * | 1999-08-30 | 2002-02-19 | Bio-Rad Laboratories, Inc. | Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
| US6414036B1 (en) * | 1999-09-01 | 2002-07-02 | Van Beek Global/Ninkov Llc | Composition for treatment of infections of humans and animals |
| AU2003228666A1 (en) * | 2002-04-23 | 2003-11-10 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
-
2000
- 2000-03-01 US US09/516,078 patent/US7135191B2/en not_active Expired - Fee Related
-
2001
- 2001-02-27 AU AU2001241802A patent/AU2001241802A1/en not_active Abandoned
- 2001-02-27 EA EA200200931A patent/EA200200931A1/en unknown
- 2001-02-27 JP JP2001563083A patent/JP2003525230A/en active Pending
- 2001-02-27 EP EP20010913098 patent/EP1263410A1/en not_active Withdrawn
- 2001-02-27 CN CN01808957A patent/CN1427715A/en active Pending
- 2001-02-27 WO PCT/US2001/006221 patent/WO2001064186A1/en not_active Application Discontinuation
- 2001-02-27 MX MXPA02008492A patent/MXPA02008492A/en unknown
- 2001-02-27 CA CA 2401804 patent/CA2401804A1/en not_active Abandoned
- 2001-02-27 BR BR0109034A patent/BR0109034A/en not_active Application Discontinuation
-
2006
- 2006-10-12 US US11/580,258 patent/US20070082010A1/en not_active Abandoned
-
2009
- 2009-08-17 US US12/583,219 patent/US20090311290A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001064186A1 (en) | 2001-09-07 |
| JP2003525230A (en) | 2003-08-26 |
| US20090311290A1 (en) | 2009-12-17 |
| MXPA02008492A (en) | 2004-05-14 |
| US7135191B2 (en) | 2006-11-14 |
| CN1427715A (en) | 2003-07-02 |
| US20070082010A1 (en) | 2007-04-12 |
| EA200200931A1 (en) | 2003-04-24 |
| US20030138455A1 (en) | 2003-07-24 |
| BR0109034A (en) | 2002-12-31 |
| EP1263410A1 (en) | 2002-12-11 |
| CA2401804A1 (en) | 2001-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220362376A1 (en) | Adjuvant and vaccine compositions | |
| US8501221B2 (en) | Methods for preparing and delivering adjuvant compositions | |
| Moldoveanu et al. | Oral immunization with influenza virus in biodegradable microspheres | |
| US20090311290A1 (en) | Urogenital or anorectal transmucosal vaccine delivery system | |
| TWI272105B (en) | Cattle reproduction vaccines | |
| TWI320715B (en) | Improved mycoplasma hyopneumoniae bacterin vaccine | |
| JPH06165688A (en) | Antigenic gene vaccine and its preparation | |
| JPH06505727A (en) | Herpes simplex vaccine consisting of HSV glycoprotein gD and 3-deacylated monophosphoryl lipid A | |
| Eng et al. | PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens | |
| US6099853A (en) | Vaginal suppository vaccine for urogenital infections | |
| Russell et al. | Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases—a review | |
| JPH11509200A (en) | Clostridium difficile toxin as a mucosal adjuvant | |
| WO2006028214A1 (en) | Vaccine for oral administration | |
| Jensen et al. | Enhanced immune response in the urinary tract of the rat following vaginal immunization | |
| Mulira et al. | Humoral and secretory antibodies to Ureaplasma diversum in heifers following subcutaneous vaccination and vaginal infection. | |
| BR102021020128A2 (en) | COMPOSITION OF INTRAVAGINAL VACCINE AND INACTIVATED INTRAVAGINAL VACCINE AGAINST BOVINE ALPHAHERPESVIRUS TYPE 5 | |
| Russell et al. | Immunity to sexually transmitted infections | |
| CN115605224A (en) | Administration of homologous adenovirus vectors | |
| MXPA00002262A (en) | Vaginal suppository vaccine for urogenital infections |